Oruka Therapeutics
ORKA
20 hedge funds and large institutions have $3.29M invested in Oruka Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
81% more capital invested
Capital invested by funds: $1.82M → $3.29M (+$1.47M)
33% more funds holding
Funds holding: 15 → 20 (+5)
0.15% more ownership
Funds ownership: 0.58% → 0.73% (+0.15%)
54% less call options, than puts
Call options by funds: $23K | Put options by funds: $50K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$694K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$306K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$191K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$136K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$80K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$46K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$45K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
ORKA Hedge Fund Activity: Q4 2020 in Review
20 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2020, worth a combined $3.29M — up 81% from $1.82M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ORKA positions and 5 closed out — a net gain of 5 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $694K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $80K sold.
- 20 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2020, up from 15 in Q3 2020.
- Funds reported $3.29M of Oruka Therapeutics stock for Q4 2020, up 81% quarter-over-quarter.
- 10 funds opened new Oruka Therapeutics positions in Q4 2020 and 5 closed out, a net change of +5 holders.
- The largest Oruka Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $694K added.
- The largest Oruka Therapeutics seller in Q4 2020 was Schonfeld Strategic Advisors, an estimated $80K sold.
Based on aggregated 13F filings for Q4 2020.